These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 33819109

  • 21. Sample size calculation for testing differences between cure rates with the optimal log-rank test.
    Wu J.
    J Biopharm Stat; 2017; 27(1):124-134. PubMed ID: 26882262
    [Abstract] [Full Text] [Related]

  • 22. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
    Wang Z, Zhang Q, Xue A, Whitmore J.
    Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
    [Abstract] [Full Text] [Related]

  • 23. A comparative study to alternatives to the log-rank test.
    Dormuth I, Liu T, Xu J, Pauly M, Ditzhaus M.
    Contemp Clin Trials; 2023 May; 128():107165. PubMed ID: 36972865
    [Abstract] [Full Text] [Related]

  • 24. Sequential tests for non-proportional hazards data.
    Brückner M, Brannath W.
    Lifetime Data Anal; 2017 Jul; 23(3):339-352. PubMed ID: 26969674
    [Abstract] [Full Text] [Related]

  • 25. Sample Size Reestimation in Stochastic Curtailment Tests With Time-to-Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters.
    Sharma P, Phadnis MA.
    Pharm Stat; 2024 Aug 18. PubMed ID: 39155271
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Optimality of testing procedures for survival data in the nonproportional hazards setting.
    Arfè A, Alexander B, Trippa L.
    Biometrics; 2021 Jun 18; 77(2):587-598. PubMed ID: 32535892
    [Abstract] [Full Text] [Related]

  • 29. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
    Phadnis MA, Wetmore JB, Mayo MS.
    Stat Med; 2017 Nov 20; 36(26):4121-4140. PubMed ID: 28815655
    [Abstract] [Full Text] [Related]

  • 30. Power and sample size calculation for log-rank test with a time lag in treatment effect.
    Zhang D, Quan H.
    Stat Med; 2009 Feb 28; 28(5):864-79. PubMed ID: 19152230
    [Abstract] [Full Text] [Related]

  • 31. Robust group sequential designs for trials with survival endpoints and delayed response.
    Ghosh P, Ristl R, König F, Posch M, Jennison C, Götte H, Schüler A, Mehta C.
    Biom J; 2022 Feb 28; 64(2):343-360. PubMed ID: 34935177
    [Abstract] [Full Text] [Related]

  • 32. Power comparisons for group sequential tests with nonparametric statistics in case of nonproportional hazards.
    Demirhan H, Demirhan YP, Bacanli S.
    J Biopharm Stat; 2013 Mar 11; 23(2):447-60. PubMed ID: 23437950
    [Abstract] [Full Text] [Related]

  • 33. A win ratio approach for comparing crossing survival curves in clinical trials.
    Zheng S, Wang D, Qiu J, Chen T, Gamalo M.
    J Biopharm Stat; 2023 Jul 04; 33(4):488-501. PubMed ID: 36749067
    [Abstract] [Full Text] [Related]

  • 34. Two-sample inference procedures under nonproportional hazards.
    Tai YC, Wang W, Wells MT.
    Pharm Stat; 2023 Jul 04; 22(6):1016-1030. PubMed ID: 37429738
    [Abstract] [Full Text] [Related]

  • 35. Comparison between asymptotic and re-randomisation tests under non-proportional hazards in a randomised controlled trial using the minimisation method.
    Kimura R, Nomura S, Nagashima K, Sato Y.
    BMC Med Res Methodol; 2024 Jul 30; 24(1):166. PubMed ID: 39080523
    [Abstract] [Full Text] [Related]

  • 36. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
    Liu S, Chu C, Rong A.
    Pharm Stat; 2018 Sep 30; 17(5):541-554. PubMed ID: 30058101
    [Abstract] [Full Text] [Related]

  • 37. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
    Chu C, Liu S, Rong A.
    Pharm Stat; 2020 Jul 30; 19(4):358-369. PubMed ID: 31930622
    [Abstract] [Full Text] [Related]

  • 38. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L, Tian L, Uno H, Solomon SD, Pfeffer MA, Schindler JS, Wei LJ.
    Clin Trials; 2012 Oct 30; 9(5):570-7. PubMed ID: 22914867
    [Abstract] [Full Text] [Related]

  • 39. Non-proportional hazards in immuno-oncology: Is an old perspective needed?
    Magirr D.
    Pharm Stat; 2021 May 30; 20(3):512-527. PubMed ID: 33350587
    [Abstract] [Full Text] [Related]

  • 40. On information fraction for Fleming-Harrington type weighted log-rank tests in a group-sequential clinical trial design.
    Kundu MG, Sarkar J.
    Stat Med; 2021 May 10; 40(10):2321-2338. PubMed ID: 33624861
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.